Clinical performance of endobronchial ultrasound‐guided transbronchial needle aspiration for assessing programmed death ligand‐1 expression in nonsmall cell lung cancer

Files

Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death.pdf (409.96 KB)

Date

2018

Type:

Article

Collections

Artículos Medicina y Ciencias de la Salud

Descargas totales

19

Vistas totales

0
Gestores bibliográficos

Authors

item.contributor.advisor

ORCID:

Journal Title

Journal ISSN

Volume Title

Publisher

Wiley Periodicals, Inc.

item.page.isbn

item.page.issn

item.page.issne

item.page.doiurl

URI

http://hdl.handle.net/11447/2515
 doi: 10.1002/dc.23900.

item.page.extent

item.page.accessRights

item.page.other

item.page.references

Abstract

Background: Pembrolizumab was recently approved as a first line agent for metastatic NSCLC in patients with high programmed death-ligand 1 (PD-L1) expression. Objetives: Since a significant portion of...

Description

item.page.coverage.spatial

item.page.sponsorship

Citation

Diagn Cytopathol. 2018 May;46(5):378-383. doi: 10.1002/dc.23900.

Keywords

PD-L1 , Endobronchial ultrasound , Immunotherapy , Nonsmall cell lung cancer , Pembrolizumab

item.page.dc.rights

item.page.dc.rights.url

Estadísticas de uso
1 0,8 0,5 0,3 0
Agosto 2025Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026

Implementado por OpenGeek Services